The nation’s drug problem is commercial recreational pharmacology

The nation’s drug problem is commercial recreational pharmacology
Drs. Robert L. DuPont and Sharon Levy have written a brilliant paper that calls on us to view the drug problem as commercial recreational pharmacology, which they define as “the personally controlled use of psychoactive drugs that super-stimulate brain reward for pleasure.” Greater acceptance of drug use and its commercialization is exacting a toll on the nation’s public health. One example is a decline in US life expectancy, which fell three years in a row from 2016 and was driven by overdose deaths.

The researchers explain that until the 1960s, most drug use was confined to just a few drugs. But as the baby boom generation became adolescents, drug use began to be more tolerated, and an array of drugs gradually became available. This shift led to today’s opioid epidemic, marijuana legalization, and the youth vaping epidemic.

New drugs and new ways to consume them add up to huge profits for their makers. Americans spend $254 billion on alcohol, $125 billion on tobacco, and $150 billion on illicit drugs.  And thus, the acceptance of recreational pharmacology in the 60s has morphed into commercialized recreational pharmacology today.

The researchers advise “a seismic shift in our shared cultural understanding of recreational drug use from one promoted by both legal and illegal commercial interests to one based on public health science that recognizes recreational drug use as a major health risk behavior.”

We highly recommend this paper to our readers for the authors’ insights into the overall drug problem and their intelligent advice on how we can resolve it. Only the abstract is available for free, but you can “rent” the article for 48-hour online access for $7. It’s well worth the money.

Read Alcoholism and Drug Abuse Weekly abstract here.

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Related Posts

Sentinel Surveillance of Substance-Related Poisonings in Canada: Spotlight on Cannabis

Substance-related poisonings and injuries in Canada have received increasing attention in recent years due to emerging public health concerns, such as the opioid overdose crisis, the introduction of synthetic cannabinoids to the illicit market and the emergence of electronic cigarettes/vaping products on the Canadian market. Furthermore, there has been a general increase in substance-related hospitalizations

Changes in Rates of Hospitalizations due to Cannabis Harms in Ontario, Canada Before the Legalization of Nonmedical Cannabis: Retrospective Population-level Study Between 2003 and 2017

There are distinct patterns of hospitalizations due to cannabis harms in different priority populations. Young women aged 15 to 24 are a key demographic that is disproportionately burdened with a rapid increase in hospitalizations due to cannabis harms. Jurisdictions considering new approaches to cannabis control policy and addiction services should consider the rising burden of

Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”

Nonmedical (“recreational”) cannabis use and cannabis laws have changed over the past two decades in the United States (1) and the rest of the world (2). Increasing use, especially among the young, coupled with the increasing potency of cannabis (higher delta-9-tetrahydrocannabinol [THC] content) during this period (3), has raised concerns about the long-term health impact

Scroll to Top